87291-34-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-chloroethoxy)-3-nitrobenzene is used as an intermediate in the synthesis of pharmaceuticals for its ability to be chemically modified and incorporated into drug molecules. Its presence in the molecular structure can contribute to the development of new medications with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(2-chloroethoxy)-3-nitrobenzene is utilized as an intermediate in the production of agrochemicals. Its chemical properties allow it to be a part of the formulation of pesticides, herbicides, and other agricultural chemicals that are designed to protect crops and enhance agricultural productivity.
Used in Dye and Pigment Production:
1-(2-chloroethoxy)-3-nitrobenzene is also used as a building block in the creation of dyes and pigments. Its chemical composition makes it suitable for the development of colorants used in various applications, including textiles, plastics, and printing inks.
Safety Considerations:
Given that 1-(2-chloroethoxy)-3-nitrobenzene contains both a nitro group and a chlorine atom, it is potentially hazardous. It is crucial to handle and store 1-(2-chloroethoxy)-3-nitrobenzene with care to prevent any harmful effects on human health or the environment. Proper safety measures, including the use of personal protective equipment and adherence to safety protocols, are essential when working with this chemical.

Upstream product

• 554-84-7 meta-nitrophenol 
• 107-04-0 1-Bromo-2-chloroethane 
• 78-93-3 butanone 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 114158-65-5 1-[2-(3-nitro-phenoxy)-ethyl]-4-phenyl-piperidine-4-carboxylic acid ethyl ester 
• 112677-69-7 1-<2-(3-nitrophenoxy)ethyl>-1H-imidazole 
• 891856-25-0 1-methyl-4-(2-(3-nitrophenoxy)ethyl)piperazine 
• 890652-00-3 3-(2-(4-methylpiperazin-1-yl)ethoxy)aniline 

Relevant academic research and scientific papers

Design, synthesis, and biological study of 4-[(2-nitroimidazole-1h-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia

Purpose: In order to get novel EGFR inhibitors exerting more potency in tumor hypoxia than in normoxia. Methods: A series of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines were designed and synthesized, and their in vitro cytotoxicity and EGFR inhibitory activity were evaluated. Molecule docking study was performed for the representative compound. Results: The structure-activity relationship (SAR) studies revealed that compounds bearing both meta-chloride and para-(2-nitroimidazole-1H-alkyloxy) groups on the aniline displayed potent inhibitory activities both in enzymatic and cellular levels. The most promising compound 16i potently inhibited EGFR with an IC50 value of 0.12 μM. Meanwhile, it manifested more potent cytotoxicity than the positive control lapatinib under tumor normoxia and hypoxia conditions (IC50 values of 1.59 and 1.09 μM against A549 cells, 2.46 and 1.35 μM against HT-29 cells, respectively). The proposed binding model of 16i in complex with EGFR was displayed by the docking results. Conclusion: This study provides insights for developing hypoxia-activated kinase inhibitors.

Fine tuning of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine focusing on the activity-sensitive aminoalkoxy moiety for a therapeutically useful inhibitor of receptor for advanced glycation end products (RAGE)

Through the fine tuning of the activity-sensitive aminoalkoxy moiety of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine as a novel inhibitor of the receptor for advanced glycation end products (RAGE), the tertiary amine was elucidated as an essential part associated with RAGE inhibition. On the basis of this finding, a 3-(N,N-dimethylamino)pyrrolidine analog 12o was identified as a therapeutically useful RAGE inhibitor with improved activity and solubility. Molecular modeling studies predicted that the improved inhibitory activity is induced by additional hydrogen bonds between the nitrogen atom of the pyrrolidine ring and Arg48 and by an interaction between the dimethylamino-substituent of the pyrrolidine moiety and a relatively hydrophobic groove in the RAGE binding site.

2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates

Described in this report is a systematic study which led to the identification of two new dopamine D2 partial agonists (5 and 17). Phenols 5 and 17 represent prototypes of two new classes of D2 partial agonist as well as templates for the future design of novel dopaminergic agents.

4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines

This disclosure describes novel 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines having anti-asthmatic activity.